Medico Intercontinental Limited has successfully submitted its Annual Secretarial Compliance Report for the financial year ended 31st March, 2026, demonstrating exemplary regulatory compliance across all examined parameters. The report was submitted to BSE Limited on April 16, 2026, in accordance with Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Clean Compliance Record Achieved

The secretarial compliance report, conducted by M/s. Agarwal & Mehta Company Secretaries LLP, revealed no deviations or violations during the period under review. The comprehensive examination covered multiple SEBI regulations and guidelines, with the company achieving full compliance across all applicable areas.

Regulatory Framework Examination

The compliance assessment examined adherence to key SEBI regulations including:

• Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
• Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
• Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015
• Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018

Several regulations were not subject to examination as no related activities were undertaken during the review period, including Issue of Capital, Buyback of Securities, Share Based Employee Benefits, and Issue and Listing of Non-Convertible Securities regulations.

Key Compliance Highlights

The report highlighted several areas of strong compliance performance:

Corporate Governance Excellence:

• All required policies adopted with board approval and timely updates
• Functional website maintained with proper document dissemination
• Performance evaluation conducted for Board, Independent Directors, and Committees

Regulatory Adherence:

• All related party transactions obtained prior audit committee approval
• Complete compliance with Regulation 30 disclosure requirements within prescribed timelines
• Proper insider trading regulation compliance maintained

Notable Regulatory Interaction

The report disclosed that the company received a compliance observation notice from BSE Limited regarding Regulation 46 of SEBI (LODR) 2015 related to website disclosures. The company promptly addressed all required updates, and no further action was initiated by BSE Limited, demonstrating responsive compliance management.

Professional Certification

The compliance report was certified by Yash Mehta, Partner at Agarwal & Mehta Company Secretaries LLP, with FCS No. 12143 and C.P. No. 16535. The certification was issued on April 16, 2026, from Ahmedabad, with UDIN: F012143H000114432 and Peer Review No. 6717/2025.

The clean compliance record reflects Medico Intercontinental Limited's commitment to maintaining high standards of corporate governance and regulatory adherence, providing confidence to stakeholders about the company's operational integrity and compliance culture.

Medico Intercontinental Limited has formally notified stock exchanges that it does not fall under the Large Corporate category as defined by SEBI's regulatory framework for debt securities fund raising. The company submitted this annual disclosure on April 8, 2026, to both BSE Limited and CSE-India as part of its regulatory compliance obligations.

SEBI Regulatory Framework Compliance

The disclosure was made pursuant to SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, which established specific guidelines for fund raising through debt securities by Large Corporates. This circular mandates particular disclosures and compliance requirements for entities classified as Large Corporates under the regulatory framework.

Exchange Notification Details

The company submitted identical notifications to both stock exchanges where its shares are listed:

Company Leadership Authorization

The disclosure was jointly signed by key company officials, demonstrating proper corporate governance protocols. Puneeta Sharma, Company Secretary & Compliance Officer, and Jay Sharadkumar Shah, Chief Financial Officer, both digitally signed the submission, ensuring authenticity and accountability.

Regulatory Significance

By confirming its non-classification as a Large Corporate, Medico Intercontinental Limited clarifies that it is not subject to the enhanced disclosure and compliance requirements that apply to larger entities under the SEBI framework. This classification affects the company's regulatory obligations when considering future debt securities issuance and related fund raising activities.

The company's proactive submission of this annual disclosure demonstrates its commitment to maintaining transparency with regulatory authorities and ensuring full compliance with applicable SEBI guidelines and exchange listing requirements.